Zidan J, Robenstein W, Abzah A, Taman S
Oncology Unit, Sieff Government Hospital, Safed, Israel.
Isr Med Assoc J. 2001 Apr;3(4):251-3.
Classic Kaposi's sarcoma is a rare tumor with an indolent behavior. Local therapy is not applicable in disseminated cutaneous disease. Patients with advanced disease are usually treated with systemic chemotherapy.
To assess the effectiveness and toxicity of single-agent vinblastine in the treatment of disseminated and recurrent Kaposi's sarcoma.
Ten patients with wide cutaneous spread of classic Kaposi's sarcoma were treated with single-agent vinblastine, 6 mg/m2 intravenously once every 2 weeks. Vinblastine was continued for 2 months after achieving a maximal response.
The male:female ratio was 2.3:1, and median age 64 years (range 50-79 years). The median number of involved nodules in the skin was 34. The overall response rate was 90%, 5 with complete response (50%) and 4 with partial response (40%). Complete responders had a longer duration of response than partial responders: 41.2 vs. 14.8 months. The median survival of all patients was 33 months. Side effects were minimal and tolerable.
Vinblastine is very effective in the treatment of extensive classic 'Kaposi's sarcoma, and results in a high response rate, long survival and disease-free survival with tolerable toxicity.
经典型卡波西肉瘤是一种行为惰性的罕见肿瘤。局部治疗不适用于播散性皮肤疾病。晚期疾病患者通常采用全身化疗。
评估单药长春碱治疗播散性和复发性卡波西肉瘤的有效性和毒性。
10例经典型卡波西肉瘤皮肤广泛播散的患者接受单药长春碱治疗，静脉注射6mg/m²，每2周1次。长春碱在达到最大反应后持续使用2个月。
男女比例为2.3:1，中位年龄64岁（范围50 - 79岁）。皮肤受累结节的中位数为34个。总缓解率为90%，5例完全缓解（50%），4例部分缓解（40%）。完全缓解者的缓解持续时间长于部分缓解者：41.2个月对14.8个月。所有患者的中位生存期为33个月。副作用轻微且可耐受。
长春碱在治疗广泛的经典型卡波西肉瘤方面非常有效，可导致高缓解率、长生存期和无病生存期，且毒性可耐受。
